Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

Biotechnology • Healthcare • Los Altos, CA, United States • UNCY (NCM)

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.

650 351 4495 4300 El Camino Real, Los Altos, CA 94022, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

New pill for dialysis patients moves ahead as FDA review restarts - Stock Titan
Stock Titan • Dec 29
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
The Business Journals • Dec 29
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewswire
GlobeNewswire • Dec 29
When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit? - Yahoo Finance
Yahoo Finance • Oct 14
UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics - TipRanks
TipRanks • Sep 30

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Unicycive Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Unicycive Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Unicycive Therapeutics, Inc. have?
Unicycive Therapeutics, Inc. has approximately 22 employees.
What industry is Unicycive Therapeutics, Inc. in?
Unicycive Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Unicycive Therapeutics, Inc. a publicly traded company?
Yes, Unicycive Therapeutics, Inc. is publicly traded under the ticker symbol UNCY on the NCM. The company has a market capitalization of approximately $0.13 billion.
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc. is headquartered in Los Altos, CA, United States at 4300 El Camino Real, Los Altos, CA 94022, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.